What is listed in the Wolverine Stack vial?
The photographed vial prints BPC-157/TB-500 BLEND; 10MG; BPC-157 5MG / TB-500 5MG. The Wolverine Stack catalogue name therefore has a literal two-component label comparison. The printed amounts document that particular vial label; they do not independently verify the contents. Label photograph.
The catalogue lists 10mg / 20mg variants. The photograph documents a 10MG label with its own 5MG/5MG breakdown; that image is not a separate printed breakdown for every variant. The listed amounts are presentations, rather than concentrations or clinical instructions. Label photograph.
BPC-157 human evidence
FDA's July 2026 briefing describes BPC-157 free base as a 15-amino-acid fragment of BPC. Free base identifies the evaluated material; the blend's printed BPC-157 name does not independently establish a salt form or authenticate its contents. FDA BPC-157 assessment, Label photograph.
For human evidence, FDA found reported ulcerative-colitis enema data inadequate to support BPC-157 efficacy and safety for that use. The review also distinguished the studied enema from a nominated suppository. A blend vial is a further, separate presentation; the report cannot be converted into evidence that Wolverine Stack has a clinical benefit. FDA BPC-157 assessment.
TB-500 and thymosin beta-4
FDA identifies the evaluated TB-500 as an N-acetylated synthetic seven-amino-acid fragment of thymosin beta-4. It explicitly states that the pharmacological profile of non-acetylated LKKTETQ cannot be directly transferred to TB-500. The full parent protein and the differently modified fragment are not equivalent evidence for the named component. FDA TB-500 assessment.
The July 2026 review did not identify human clinical studies administering TB-500. That is a dated assessment of the exact substance, rather than a positive clinical finding for a blend. Combining its name with BPC-157 does not remove the identity or human-evidence limits of either component. FDA TB-500 assessment, Label photograph, FDA BPC-157 assessment.
Wolverine Stack benefits and safety limits
FDA's BPC-157 compounding communication identifies potential immune-response risks, peptide impurities and difficulties characterizing the active ingredient. These are concerns about the compounded substance and proposed routes, not a test result establishing a defect in this supplier vial. They also do not supply evidence of synergy between the two printed components. FDA compounding safety communication, Label photograph.
The Wolverine Stack Pen is separately documented by its own photographed label. The 5MG/5MG breakdown above stays attached to the 10MG vial image. Similar stack names do not establish matching pen contents or interchangeable biological performance. Label photograph.
